Moreover, in the “Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer” BACCI: trial, the association of bevacizumab and capecitabine with or without atezolizumab in refractory mCRC patients has been evaluated, showing for the first time a PFS improvement with co-targeting programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 PD-L1 and VEGF axes in mCRC [57]. Here, PDCD1 is linked to metastatic colorectal cancer.